SecBot SecBot
SECBOTREPLAY Home › Report › TCRX

TCRX · TScan Therapeutics reported financial results for Q4 and full-year…

TScan Therapeutics, Inc. · PRESS-RELEASE filed Mar 4, 2026 at 07:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 4, 2026 at 07:00 ET

TScan Therapeutics reported financial results for Q4 and full-year 2025, highlighted by a 268% year-over-year increase in revenue to $10.3M driven by its Amgen collaboration, while R&D and G&A expenses declined QoQ. The company presented positive Phase 1 ALLOHA™ trial data showing improved survival trends and completed enrollment in Cohort C using its commercial-ready manufacturing process. FDA clearance of two new TCR-T candidates (TSC-102-A01/A03) expands its heme malignancy pipeline. Cash remains strong at $152.4M, sufficient to fund operations into H2 2027.

  • Q4 2025 revenue: $2.6M (vs. $0.7M in Q4 2024), full-year 2025 revenue: $10.3M (vs. $2.8M in 2024), driven by Amgen collaboration
  • Q4 2025 R&D expenses down 32% YoY to $20.0M; full-year R&D up slightly to $114.2M
  • Net loss narrowed to $23.0M in Q4 2025 (vs. $35.8M in Q4 2024)
  • Positive ALLOHA™ Phase 1 data: 100% (3/3) of TSC-101-treated patients relapse-free at 2-year follow-up vs. 25% (1/4) in control

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access